the efficacy of botulinum toxin in the treatment of Melasma

Evaluating the efficacy and safety of botulinium toxin injection on melasma treatment: A randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250228064873N1

Enrollment

Registered

2025-05-21

Start date

2025-05-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma. MELAS syndrome

Interventions

Intervention 1: Intervention group: injection of botulinum toxin(Each 500-unit vial of Masport is diluted with 5 cc of normal saline and then 3 units of Masport are injected per centimeter of melasma

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: melasma on both cheeks with symmetrical distribution

Exclusion criteria

Exclusion criteria: sensitivity to botulinum toxin use of lightening creams in the last 3 months pregnancy Lactation

Design outcomes

Primary

Measure	Time frame
Melasma Area and Severity Index (MASI). Timepoint: before intervention, 2 weeks later and 3 months later. Method of measurement: Melasma Area and Severity Index (MASI). A, Area; D, darkness, H, homogeneity; L, left, R, right. The total score range is 0 to 48.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactIfa Etesami

Tehran University of Medical Sciences

Ifa.etesami@gmail.com+98 21 5561 8989

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026